Medicare Enrolled
Dr. Luis Galvez, MD
Gastroenterology · Atlanta, GA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Galvez from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Galvez?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Galvez
Dr. Luis Galvez is a gastroenterology specialist in Atlanta, GA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Galvez performed 2,474 Medicare services across 490 unique beneficiaries.
Between the years covered by Open Payments, Dr. Galvez received a total of $6,282 from 47 pharmaceutical and/or device companies across 389 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in gastroenterology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Galvez is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 4% volume in GA
$6,282 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,474
Medicare services
Top 4% in GA for gastroenterology
490
Unique beneficiaries
$41
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~124 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
1,890 | $26 | $95 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
187 | $82 | $392 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
58 | $63 | $339 |
| Upper GI endoscopy with biopsy A procedure to collect tissue samples from the esophagus, stomach, or upper small intestine using a flexible tube with a camera. The samples are examined to check for abnormalities. |
49 | $79 | $600 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
49 | $62 | $276 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
37 | $62 | $210 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
35 | $102 | $400 |
| Colonoscopy with biopsy A procedure to collect tissue samples from the large intestine using a flexible tube with a camera. The samples are examined to check for abnormalities or disease. |
32 | $130 | $793 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
28 | $93 | $301 |
| Colon polyp removal with endoscopic snare This procedure removes polyps or growths from the large bowel using a flexible tube with a camera and a wire loop tool. The snare is used to cut off the growths during the examination. |
21 | $209 | $943 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
21 | $44 | $230 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
17 | $93 | $540 |
| Colonoscopy for colorectal cancer screening, high risk A colonoscopy performed to screen for colorectal cancer in individuals identified as being at high risk for the disease. |
13 | $173 | $747 |
| Colonoscopy for colorectal cancer screening A colonoscopy performed to screen for colorectal cancer in individuals who are not at high risk for the disease. |
13 | $174 | $747 |
| Upper endoscopy (EGD) A diagnostic exam of the esophagus, stomach, and upper small bowel using a flexible endoscope. |
12 | $92 | $408 |
| Colonoscopy A diagnostic exam of the large bowel using a flexible endoscope to visualize the interior of the colon. |
12 | $144 | $747 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
77.9% high complexity
5.3% medium
16.8% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,282
Total received (2018-2024)
Avg $897/year across 7 years
Top 33% in GA for gastroenterology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
47
Companies
389
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,018 (95.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$264 (4.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,062
2023
$1,128
2022
$1,388
2021
$1,114
2020
$307
2019
$824
2018
$460
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$352
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$106
AIMMUNE THERAPEUTICS, INC.
$93
Celltrion USA Inc.
$90
Lilly USA, LLC
$61
Ipsen Biopharmaceuticals, Inc
$58
Takeda Pharmaceuticals U.S.A., Inc.
$47
PFIZER INC.
$38
Medtronic, Inc.
$32
Madrigal Pharmaceuticals
$31
Janssen Biotech, Inc.
$30
Regeneron Healthcare Solutions, Inc.
$26
GENZYME CORPORATION
$22
Phathom Pharmaceuticals, Inc.
$21
VIVUS LLC
$19
Celgene Corporation
$18
Intercept Pharmaceuticals, Inc.
$18
Top 3 companies account for 51.9% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$937
Salix Pharmaceuticals, a division of Bausch Health US, LLC
$858
AbbVie Inc.
$548
Takeda Pharmaceuticals U.S.A., Inc.
$456
Celgene Corporation
$451
AbbVie, Inc.
$449
Janssen Biotech, Inc.
$356
PFIZER INC.
$322
Allergan Inc.
$221
INTERCEPT PHARMACEUTICALS, INC.
$149
Merck Sharp & Dohme LLC
$132
AIMMUNE THERAPEUTICS, INC.
$114
Intercept Pharmaceuticals, Inc.
$113
GENZYME CORPORATION
$111
Celltrion USA Inc.
$105
Regeneron Healthcare Solutions, Inc.
$87
VIVUS LLC
$68
Merck Sharp & Dohme Corporation
$64
Lilly USA, LLC
$61
Ipsen Biopharmaceuticals, Inc
$58
INTRA-SANA LABORATORIES
$47
Ironwood Pharmaceuticals, Inc
$44
Ardelyx, Inc.
$41
Romark Laboratories, LC
$39
Daiichi Sankyo Inc.
$35
Medtronic, Inc.
$32
Madrigal Pharmaceuticals
$31
Ambu Inc.
$30
Gilead Sciences, Inc.
$29
Ferring Pharmaceuticals Inc.
$27
RedHill Biopharma Inc.
$24
Phathom Pharmaceuticals, Inc.
$21
Sandoz Inc.
$21
Shionogi Inc
$20
Braintree Laboratories, Inc.
$18
Nestle HealthCare Nutrition Inc.
$18
Horizon Therapeutics plc
$17
Baxter Healthcare
$17
Exact Sciences Corporation
$16
Lumendi LLC
$15
Organon LLC
$14
UCB, Inc.
$13
BOSTON SCIENTIFIC CORPORATION
$13
QOL Medical, LLC
$13
AMAG Pharmaceuticals, Inc.
$12
EVOKE PHARMA, INC.
$11
Napo Pharmaceuticals Inc
$4
Top 3 companies account for 37.3% of all-time payments
Associated products mentioned in payments ›
ALINIA · Aemcolo · Alinia · Bylvay · CLENPIQ · CREON · Cimzia · Cologuard Collection Kit · Creon · DIFICID · DILUMEN · DUPIXENT · ENTYVIO · FERAHEME · FLOSEAL · GATTEX · GENERAL ENDOCHOICE · GIMOTI · HUMIRA · HYRIMOZ · Humira · IBSRELA · INJECTAFER · INTERSTIM · IQIRVO · LINZESS · Linzess · MAVYRET · MOTEGRITY · Mavyret · Motegrity · Mulpleta · Mytesi · OCALIVA · OMVOH · QSYMIA · RAYOS · RELTONE 200 MG · RENFLEXIS · RESMETIROM · RINVOQ · SKYRIZI · STELARA · SUTAB · Sucraid · TAKHZYRO · TRULANCE · UCERIS · UCERIS TABLETS · VEGZELMA · VELSIPITY · VIBERZI · VOQUEZNA · VOWST · XELJANZ · XIFAXAN · YUFLYMA · ZENPEP · ZEPOSIA · ZYMFENTRA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Gastroenterologists within 10 mi
231
Per 100K population
21.6
County median income
$91,490
Nearest hospital
SAINT JOSEPH'S HOSPITAL OF ATLANTA, INC
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Galvez is a mixed practice specialist, with above-average Medicare volume (top 4% in GA), with low-engagement industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Galvez experienced with infliximab infusion (remicade)?
Based on Medicare claims data, Dr. Galvez performed 1,890 infliximab infusion (remicade) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Galvez receive payments from pharmaceutical companies?
Yes. Dr. Galvez received a total of $6,282 from 47 companies across 389 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Galvez's costs compare to other gastroenterologists in Atlanta?
Dr. Galvez's average Medicare payment per service is $41. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Galvez) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Gastroenterology
Common procedures, typical costs, and what industry payments mean in gastroenterology.
Same specialty & city
Gastroenterologists in Atlanta
Browse gastroenterologists in Atlanta ranked by procedure volume and transparency data.
Highest volume
Top Gastroenterologists in GA
Gastroenterologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Gastroenterologists in GA
Which GA gastroenterologists receive the most from drug and device companies.
By company
ABBVIE INC. Payments to Doctors
See all physicians who received payments from ABBVIE INC.
By company
Salix Pharmaceuticals, a division of Bausch Health US, LLC Payments to Doctors
See all physicians who received payments from Salix Pharmaceuticals, a division of Bausch Health US, LLC.
By company
AbbVie Inc. Payments to Doctors
See all physicians who received payments from AbbVie Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology